SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on November 10, 2022. The report serves to disclose the Company's financial results for the quarter ended September 30, 2022, as detailed in a press release furnished as Exhibit 99.1. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It directs investors to the press release for the specific results of operations and financial condition for the quarter ended September 30, 2022.
Guidance, Outlook, and Risks
The filing includes a Regulation FD Disclosure (Item 7.01), outlining the Company's channels for communicating material information, including its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Facebook). No specific forward-looking guidance, management commentary on future performance, or detailed risk factors are provided in this specific 8-K text; such details are expected to be in the referenced press release.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as this 8-K only references them.
- Confirm the Company's name is Athira Pharma, Inc. (ATHA), noting the discrepancy with the "Leonabio, Inc." label in the request metadata.
- Review the Company's official investor relations website and social media channels for any additional material disclosures made concurrently with this filing.
- Check for any subsequent filings that may incorporate the press release by reference for detailed financial analysis.